ADVENZYMES Advanced Enzyme Technologies Q2 FY26 results (Jul–Sep 2025) and concall
Advanced Enzyme Technologies reported strong Q2 FY26 results, driven by robust growth in Human Healthcare and Specialized Manufacturing segments. Despite global uncertainties and tariff-related headwinds in the US market, the company maintained healthy margins and is focused on strategic R&D investments and international expansion. Management reiterated its mid-double digit growth guidance for the year, supported by operational efficiencies and a diversified product mix.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 50.6%, net profit up 144.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 77 | 101 | 87 | 125 | 116 +51% |
| EBITDA | 14 | 22 | 14 | 31 | 30 +114% |
| Net profit | 9 | 15 | 11 | 74 | 22 +144% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
